US vaccine advisers unanimously favor Pfizer/BioNTech shot after approval

  • 📰 inquirerdotnet
  • ⏱ Reading Time:
  • 42 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 86%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

An advisory panel to the U.S. CDC on Monday unanimously recommended the Pfizer Inc and BioNTech SE COVID-19 vaccine for people age 16 and older, an important step that could help accelerate vaccine mandates in the United States.

Some panel members said increasing vaccinations before the fall season was critical to getting children back to schools safely.

Regulators have authorized a third dose of the Pfizer/BioNTech and Moderna vaccines for those with weak immune systems, and the U.S. government has said it plans to make booster doses available to more Americans in September. CDC staff presented available data on the need for boosters and said, at this point it may be difficult to determine whether immunity from prior vaccination is waning over time or if the vaccines are just less able to prevent infection by the highly-transmissible Delta variant.

Members of the vaccine advisory working group, which is shaping the agency’s approach to boosters, stressed that the top U.S. priority remains getting shots to the unvaccinated.At Monday’s meeting, the CDC reiterated that the benefits of the Pfizer vaccine outweigh potential risks associated with the shots.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in HEALTH

Health Health Latest News, Health Health Headlines